Post-transplant lymphoproliferative disorder after liver transplantation: Incidence, long-term survival and impact of serum tacrolimus level

Table 2 Kaplan-Meier analysis of risk factors and post-transplant lymphoproliferative disorder survival of pediatric and adult patients

	Mean survival in mo	P value
Sex		0.902
Male	65.65 ± 13.18
Female	36.06 ± 5.30
Multi-organ involvement		0.002
(+)	27.13 ± 6.30
(-)	104.25 ± 9.08
CMV status		0.370
CMV-positive	51.98 ± 10.50
CMV-negative	23.29 ± 5.76
EBV status		0.002
EBV-positive	60.58 ± 7.62
EBV-negative	16.72 ± 5.66
Rejection episode		0.762
(+)	64.90 ± 13.78
(-)	65.86 ± 15.76
Time to PTLD development in years		0.704
≤ 1	62.18 ± 14.03
≥ 1	75.13 ± 12.49
Type of allograft		0.904
Living donor	50.56 ± 6.95
Deceased donor	60.32 ± 14.33

CMV: Cytomegalovirus; EBV: Epstein-Barr virus; PTLD: Post-transplant lymphoproliferative disorder.